Combination of TATE and PD-1 Inhibitor in Liver Cancer
Phase 2
54
about 8.5 years
18–80
3 sites in CA, OK, WI
What this study is about
Researchers are testing the effectiveness of Trans-arterial Tirapazamine Embolization (TATE) treatment for liver cancer, followed by a PD-1 checkpoint inhibitor (nivolumab). The trial will enroll adults with advanced hepatocellular carcinoma (HCC) and metastatic gastric cancer who have progressed on a prior immune checkpoint inhibitor.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive Nivolumab Injectable Product
- 2.Take Trans-arterial tirapazamine embolization
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
immunotherapy (Immune checkpoint inhibitor; blocks PD-1 receptor on T cells)
infusion, injection
Primary: Overall Response Rate
Secondary: Duration of Response, Overall survival, Progression Free Survival, Time to Progression